ArticleCureus2025
The Impact of Glycemic Control on Ranibizumab Efficacy in Diabetic Retinopathy: A Retrospective Analysis.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDiabetic retinopathy (DR), a leading cause of vision loss, is driven by inflammation, oxidative stress, and vascular endothelial growth factor (VEGF) production, with elevated blood glucose and advanced glycation end products (AGEs) exacerbating retinal damage. While intravitreal VEGF inhibitors have become the first-line treatment for diabetic macular edema (DME), response to therapy varies due to systemic factors such as HbA1c levels, blood pressure, and diabetes duration.
objectivesThis study aims to assess the impact of glycosylated hemoglobin (HbA1c) control on the effectiveness of Ranibizumab treatment in patients with DR. METHODOLOGY: The study included 222 eyes from 222 patients with type 2 diabetes, comprising 60% males and 40% females, with an average age of 60.2 ± 9.32 years. Participants were administered monthly intravitreal injections of Ranibizumab, 0.05 mL of a 6 mg/mL solution, over three months, and an optical coherence tomography (OCT) was done one month after the treatment for the evaluation of the patient's need for further injections. HbA1c, central retinal thickness (CRT), and best-corrected visual acuity (BCVA) were measured at the beginning and end of the study. Patients were then divided into two groups according to their HbA1c level, with a cut-off point of 7% (53 mmol/mol).
resultsAt the beginning of the study, the HbA1c mean was 8.16% ± 1.2%, the BCVA mean was 59.7 ± 9.73, and the central macular thickness (CMT) mean was 465.4 ± 132.34 µm. Twelve months later, the 222 patients were separated into two groups based on HbA1c levels: 109 patients had an HbA1c >7% (group A) and 113 patients had an HbA1c ≤7% (group B). The improvement of BCVA was 6.1 ± 7.3 for group A versus 7.9 ± 6.1 for group B (
conclusionsOur study indicates that HbA1c control influences the treatment outcomes of intravitreal Ranibizumab for DME, with better responses observed in patients whose HbA1c is below 7%.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.